Cargando…
Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes
PURPOSE: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs) have demonstrated efficacy in treating advanced non-small-cell lung cancer (NSCLC). Preliminary findings suggested that EGFR–TKIs might also be beneficial in neoadjuvant therapy in treating NSCLC. Therefore, this study...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809345/ https://www.ncbi.nlm.nih.gov/pubmed/27042123 http://dx.doi.org/10.2147/OTT.S93823 |
_version_ | 1782423624057094144 |
---|---|
author | Wang, Tao Liu, Yang Zhou, Bin Wang, Zhi Liang, Naichao Zhang, Yundong Dong, Zhouhuan Li, Jie |
author_facet | Wang, Tao Liu, Yang Zhou, Bin Wang, Zhi Liang, Naichao Zhang, Yundong Dong, Zhouhuan Li, Jie |
author_sort | Wang, Tao |
collection | PubMed |
description | PURPOSE: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs) have demonstrated efficacy in treating advanced non-small-cell lung cancer (NSCLC). Preliminary findings suggested that EGFR–TKIs might also be beneficial in neoadjuvant therapy in treating NSCLC. Therefore, this study aimed to evaluate the efficacy and safety of neoadjuvant therapy with icotinib in patients with early-stage NSCLC. PATIENTS AND METHODS: We retrospectively reviewed the medical history of patients who were initially diagnosed with stage IA–IIIA NSCLC and were under icotinib administration before surgery between December 2011 and December 2014. Tumor assessment was conducted between the second and fourth week from initial icotinib treatment. The association between personal characteristics, smoking status, disease stage, EGFR mutation status, and clinical outcomes were investigated using multivariate logistic regression analysis. RESULTS: A total of 67 patients with NSCLC were reviewed, and approximately half (38/67) of them were identified as having EGFR-mutant tumors. The overall response rate of all patients was 26.7% at 2–4 weeks’ assessment. Multivariate analysis showed that female sex (38.5% versus 10.7% in males, P=0.028) and EGFR mutation status (42.1% versus 6.9% in EGFR wild type, P=0.011) were independent predictive factors. The analysis also showed that the most common adverse effects were rash (43.3%) and dry skin (34.4%), which were tolerable. CONCLUSION: Icotinib induced clinical response with minimal toxicity as neoadjuvant treatment in early NSCLC, especially in patients with common EGFR mutations. Further studies are warranted to confirm our findings. |
format | Online Article Text |
id | pubmed-4809345 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48093452016-04-01 Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes Wang, Tao Liu, Yang Zhou, Bin Wang, Zhi Liang, Naichao Zhang, Yundong Dong, Zhouhuan Li, Jie Onco Targets Ther Original Research PURPOSE: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs) have demonstrated efficacy in treating advanced non-small-cell lung cancer (NSCLC). Preliminary findings suggested that EGFR–TKIs might also be beneficial in neoadjuvant therapy in treating NSCLC. Therefore, this study aimed to evaluate the efficacy and safety of neoadjuvant therapy with icotinib in patients with early-stage NSCLC. PATIENTS AND METHODS: We retrospectively reviewed the medical history of patients who were initially diagnosed with stage IA–IIIA NSCLC and were under icotinib administration before surgery between December 2011 and December 2014. Tumor assessment was conducted between the second and fourth week from initial icotinib treatment. The association between personal characteristics, smoking status, disease stage, EGFR mutation status, and clinical outcomes were investigated using multivariate logistic regression analysis. RESULTS: A total of 67 patients with NSCLC were reviewed, and approximately half (38/67) of them were identified as having EGFR-mutant tumors. The overall response rate of all patients was 26.7% at 2–4 weeks’ assessment. Multivariate analysis showed that female sex (38.5% versus 10.7% in males, P=0.028) and EGFR mutation status (42.1% versus 6.9% in EGFR wild type, P=0.011) were independent predictive factors. The analysis also showed that the most common adverse effects were rash (43.3%) and dry skin (34.4%), which were tolerable. CONCLUSION: Icotinib induced clinical response with minimal toxicity as neoadjuvant treatment in early NSCLC, especially in patients with common EGFR mutations. Further studies are warranted to confirm our findings. Dove Medical Press 2016-03-22 /pmc/articles/PMC4809345/ /pubmed/27042123 http://dx.doi.org/10.2147/OTT.S93823 Text en © 2016 Wang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Wang, Tao Liu, Yang Zhou, Bin Wang, Zhi Liang, Naichao Zhang, Yundong Dong, Zhouhuan Li, Jie Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes |
title | Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes |
title_full | Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes |
title_fullStr | Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes |
title_full_unstemmed | Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes |
title_short | Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes |
title_sort | effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809345/ https://www.ncbi.nlm.nih.gov/pubmed/27042123 http://dx.doi.org/10.2147/OTT.S93823 |
work_keys_str_mv | AT wangtao effectsoficotinibonearlystagenonsmallcelllungcancerasneoadjuvanttreatmentwithdifferentepidermalgrowthfactorreceptorphenotypes AT liuyang effectsoficotinibonearlystagenonsmallcelllungcancerasneoadjuvanttreatmentwithdifferentepidermalgrowthfactorreceptorphenotypes AT zhoubin effectsoficotinibonearlystagenonsmallcelllungcancerasneoadjuvanttreatmentwithdifferentepidermalgrowthfactorreceptorphenotypes AT wangzhi effectsoficotinibonearlystagenonsmallcelllungcancerasneoadjuvanttreatmentwithdifferentepidermalgrowthfactorreceptorphenotypes AT liangnaichao effectsoficotinibonearlystagenonsmallcelllungcancerasneoadjuvanttreatmentwithdifferentepidermalgrowthfactorreceptorphenotypes AT zhangyundong effectsoficotinibonearlystagenonsmallcelllungcancerasneoadjuvanttreatmentwithdifferentepidermalgrowthfactorreceptorphenotypes AT dongzhouhuan effectsoficotinibonearlystagenonsmallcelllungcancerasneoadjuvanttreatmentwithdifferentepidermalgrowthfactorreceptorphenotypes AT lijie effectsoficotinibonearlystagenonsmallcelllungcancerasneoadjuvanttreatmentwithdifferentepidermalgrowthfactorreceptorphenotypes |